参考文献/References:
[1] O’Neil LJ, Kaplan MJ, Carmona-Rivera C. The role of neutrophils and neutrophil extracellular traps in vascular damage in systemic lupus erythematosus[J]. J Clin Med, 2019,8(9). pii: E1325. doi: 10.3390/jcm8091325[2] Urowitz MB, Bookman AA, Koehler BE, et al. The bimodal mortality pattern of systemic lupus erythematosus[J]. Am J Med,1976,60(2):221-225.
[3] Wu GC, Liu HR, Leng RX, et al. Subclinical atherosclerosis in patients with systemic lupus erythematosus: A systemic review and meta-analysis[J]. Autoimmun Rev, 2016,15(1):22-37.
[4] Fernandez-Nebro A, Rua-Figueroa I, Lopez-Longo FJ, et al. Cardiovascular events in systemic lupus erythematosus: A nationwide study in Spain from the RELESSER registry[J]. Medicine (Baltimore),2015,94(29):e1183.
[5] Lin CY, Shih CC, Yeh CC, et al. Increased risk of acute myocardial infarction and mortality in patients with systemic lupus erythematosus: two nationwide retrospective cohort studies[J]. Int J Cardiol, 2014,176(3):847-851.
[6] Bruce IN, Gladman DD, Urowitz MB. Premature atherosclerosis in systemic lupus erythematosus[J]. Rheum Dis Clin North Am, 2000,26(2):257-278.
[7] Manzi S, Meilahn EN, Rairie JE, et al. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham study[J]. Am J Epidemiol, 1997,145(5):408-415.
[8] Giannelou M, Mavragani CP. Cardiovascular disease in systemic lupus erythematosus: A comprehensive update[J]. J Autoimmun, 2017,82:1-12.
[9] Park JK, Kim JY, Moon JY, et al. Altered lipoproteins in patients with systemic lupus erythematosus are associated with augmented oxidative stress: a potential role in atherosclerosis[J]. Arthritis Res Ther,2016,18(1):306.
[10] 蒋晖,汪汉,蔡琳.抗磷脂抗体综合征的心血管病变[J].心血管病学进展,2014,35(1):79-84.
[11] Perezsanchez C, Barbarroja N, Messineo S, et al. Gene profiling reveals specific molecular pathways in the pathogenesis of atherosclerosis and cardiovascular disease in antiphospholipid syndrome, systemic lupus erythematosus and antiphospholipid syndrome with lupus[J]. Ann Rheum Dis,2015,74(7):1441-1449.
[12] O’Neill SG, Giles I, Lambrianides A, et al. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus[J]. Arthritis Rheum,2010,62(3):845-854.
[13] Khamashta M, Merrill JT, Werth VP, et al. Sifalimumab, an anti-interferon-alpha monoclonal antibody, in moderate to severe systemic lupus erythematosus: a randomised, double-blind, placebo-controlled study[J]. Ann Rheum Dis, 2016,75(11): 1909-1916.
[14] Ramji DP, Davies TS. Cytokines in atherosclerosis: key players in all stages of disease and promising therapeutic targets[J]. Cytokine Growth Factor Rev, 2015,26(6):673-685.
[15] Buie JJ, Renaud LL, Muise-Helmericks R, et al. IFN-alpha negatively regulates the expression of endothelial nitric oxide synthase and nitric oxide production: Implications for systemic lupus erythematosus[J].J Immunol,2017,199(6): 1979-1988.
[16] Moreno JA, Ortega-Gomez A, Delbosc S, et al. In vitro and in vivo evidence for the role of elastase shedding of CD163 in human atherothrombosis[J]. Eur Heart J, 2012,33(2):252-263.
[17] Jacobi J, Sela S, Cohen HI, et al. Priming of polymorphonuclear leukocytes: a culprit in the initiation of endothelial cell injury[J]. Am J Physiol Heart Circ Physiol, 2006,290(5):H2051-2058.
[18] Leclercq A, Houard X, Philippe M, et al. Involvement of intraplaque hemorrhage in atherothrombosis evolution via neutrophil protease enrichment[J]. J Leukoc Biol, 2007,82(6):1420-1429.
[19] Mozzini C, Garbin U, Fratta Pasini AM, et al. An exploratory look at NETosis in atherosclerosis[J]. Intern Emerg Med,2017,12(1):13-22.
[20] Galluzzi L, Vitale I, Aaronson SA, et al. Molecular mechanisms of cell death: recommendations of the nomenclature committee on cell death 2018[J]. Cell Death Differ, 2018,25(3):486-541.
[21] Caielli S, Athale S, Domic B, et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus[J].J Exp Med, 2016,213(5):697-713.
[22] Liu Y, Kaplan MJ. Cardiovascular disease in systemic lupus erythematosus: an update[J]. Curr Opin Rheumatol, 2018,30(5):441-448.
[23] 王燕凤,蔡琳,汪汉.心肌组织中巨噬细胞的稳定性及特异性[J].心血管病学进展,2019,40(1):121-124.
[24] 张翠,蔡琳,汪汉.结缔组织病与心力衰竭[J].心血管病学进展,2018,39(4): 677-681.
[25] Reynolds J, Ray D, Alexander MY, et al. Role of vitamin D in endothelial function and endothelial repair in clinically stable systemic lupus erythematosus[J]. Lancet,2015,385( Suppl 1):S83.
[26] Svenungsson E, Engelbertsen D, Wigren M, et al. Decreased levels of autoantibodies against apolipoprotein B-100 antigens are associated with cardiovascular disease in systemic lupus erythematosus[J]. Clin Exp Immunol, 2015,181(3):417-426.
[27] Tumurkhuu G, Montano E, Jefferies C. Innate immune dysregulation in the development of cardiovascular disease in lupus[J]. Curr Rheumatol Rep, 2019,21(9):46.
[28]Bessant R, Duncan R, Ambler G, et al. Prevalence of conventional and lupus-specific risk factors for cardiovascular disease in patients with systemic lupus erythematosus: A case-control study[J]. Arthritis Rheum, 2006,55(6):892-899.